Natco Pharma Approves Rights Issue of ₹1,279 Crore at ₹750/Share
Natco Pharma approved a rights issue of ₹1,279.36 crore, offering 1.70 crore shares at ₹750 each. The issue opens on October 12, 2026, and closes on October 22, 2026. The record date is October 1, 2026, with a ratio of 2 shares for every 21 held.
A rights issue of this magnitude can significantly impact the company's capital structure, share count, and future financial performance.
The approval of a significant rights issue to raise capital is generally viewed positively as it indicates a growth or expansion plan.
Natco Pharma Limited's Board of Directors, in a meeting held on September 25, 2026, approved a Rights Issue of equity shares aggregating up to ₹1,279.36 crore (₹12,793,561,500). The issue comprises 1,70,58,082 equity shares with a face value of ₹2 each, offered at a price of ₹750 per share, including a premium of ₹748.
The Rights Issue will be open from Monday, October 12, 2026, to Thursday, October 22, 2026. The record date for determining eligible shareholders is October 1, 2026. Eligible equity shareholders will receive 2 Rights Equity Shares for every 21 fully paid-up Equity Shares held on the record date. The on-market renunciation period will be from October 12, 2026, to October 16, 2026.
Additionally, the Board approved an amendment to the Code of Conduct to regulate, monitor, and report trading by designated persons. The meeting commenced at 10:30 a.m. and concluded at 11:00 a.m.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.